5 Key Insights on US$85 Bn Opportunity in Global Biomarkers Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Driven by the rising prevalence of chronic and neurodegenerative diseases and the growing popularity of remote technologies such as medical wearables, the Global Biomarkers Market is Forecasted to Cross US$85 Bn by 2028 says Ken Research Study. A biomarker, also known as a biological marker, is an objective measure used to indicate that a biological process in the body has occurred or is currently occurring. While some biomarkers are used to demonstrate that the body has been exposed to a chemical, toxin, or other environmental hazards, the majority of biomarkers are associated with medicine. Several biomarkers are derived from simple observations made during a routine medical appointment, such as blood pressure or body composition. Other biomarkers are based on laboratory tests of blood, urine, or tissues, and some can detect changes at the molecular and cellular level by examining genes or proteins. According to Ken Research estimates, the Global Biomarkers Market – which grew from around US$ 27 Bn in 2017 to nearly US$40 Bn in 2021 – is expected to grow further into a more than US$85 Bn opportunity by 2028 – “Ken Research shares 5 key insights on this high opportunity market from its latest research study” Biomarkers have seen Accelerated Growth after Several Proactive Interventions and Rising Funding for the Diagnosis of Multiple Disorders and Diseases. The Global Biomarkers Market is expected to witness strong growth during the forecast period, owing to increasing favorable government initiatives concerning drug development or research, along with soaring digital healthcare funding. For instance, in July 2022, the National Institute of Neurological Disorders and Stroke (NINDS) stated that its Biomarker Program, which was initiated in 2012 to expedite the discovery of exploring new diagnostic and progression biomarkers for Parkinson’s Disease, nowadays is focusing on increasing the efficiency and effectiveness of neurotherapeutic clinical research by supporting rigorous biomarker advancement and validation. In addition, to achieve such a goal, the program: Promotes stringent biomarker identification and validation through funding opportunities. Facilitates the creation of potential resources primarily directed at filling gaps in the biomarker testing process. Furthermore, on November 2, 2021, Members of the European Platform for Neurodegenerative Diseases (EPND), which was established by the EU for the storage and analysis of high-quality clinical and biological samples and data collections, announced that they will embark on an initiative to establish a unified platform for efficient sample and data exchange, leveraging, and connecting existing European research infrastructures to boost the discovery of biomarkers, new diagnostics, and treatments for people with neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The Rising Prevalence of Chronic and Neurodegenerative Diseases and Growing Popularity of Remote Technologies are Major Growth Drivers for Global Biomarkers Market. The increasing prevalence of chronic and neurodegenerative diseases, including Neurodegenerative disorders, Alzheimer’s disease (AD), and Parkinson’s disease (PD) due to an aging population, has led to increasing demand for improved drug development or research to effectively combat these diseases. For instance, according to Alzheimer’s Disease Association, a U.S.-based non-profit organization, presently nearly 6.2 million individuals in the U.S. have Alzheimer’s disease, a progressive neurologic disorder that leads the brain to shrink and brain cells to die. According to Parkinson’s Foundation, a U.S.-based non-profit organization, nearly a million Americans have Parkinson’s disease (PD), a brain disorder that leads to unrestrained movements such as wobbling, stiffness, and difficulty with balance and coordination, with the number expected to increase to 1.2 million by 2030. In addition, over 10 million people worldwide are currently affected by Parkinson’s disease (PD). Furthermore, the rising cost of drug development, the proliferation of wearable devices in healthcare, and rising smartphone penetration have all contributed to the increased demand for digital biomarkers (DBMs). In addition, multiple digital healthcare applications are available on Google Play and iOS that are allowing users to track biological functions such as sleep, heartbeat, and movement, thereby supporting the growth of the biomarker market. Digital Diagnostics and Digital Therapeutic Medical Devices have Emerged as an Immersive Opportunity for Healthcare Innovation. The majority of the ongoing evolution in the life sciences industry is being driven by technology. The rise of digital health is likely to be a defining aspect of the industry in the forthcoming years. The influence of digital health and artificial intelligence (AI) will extend beyond even innovative products like wearables and diagnostics, as well as new processes like decentralized clinical trials. AI technologies will become more widely accessible and affordable with the introduction of cloud-based, off-the-shelf AI tools. Furthermore, the emergence of wearables and mobile health (mHealth) technologies will enable more efficient collection and analysis of digital biomarkers, and provide valuable data for AI systems applications. The Drug Discovery & Development Segment is Likely to Grow Significantly during the Forecasted Period. The extensive R&D initiatives for the development of therapeutic, and the ability of biomarkers to foresee drug efficacy more effectively with its high-speed approval process, are fuelling its demand in drug discovery and development. The ongoing covid-19 pandemic also strengthens the utilization of biomarkers in drug discovery and development, due to increased investment and advancement in innovative therapeutics and vaccines across a wide range of disease aspects. As per industry estimates, the number of clinical trials has witnessed steady growth from 2015 to 2021, including a jump in 2021 resulting from COVID-19 vaccination trials. North America is the Pioneer and Largest Market of Biomarkers Owing to the Increased Adoption of Advanced Technologies, a Strong Base of Healthcare Facilities, and Rising Investments from Key players in the Development of Advanced Devices. The growth of biomarkers in North America is being attributed to the rising burden of chronic disease, notably in the U.S., growing consumer awareness, proactive government interventions, technology advancements, and improvements in healthcare infrastructure. Furthermore, the increased prevalence of precision/personalized medicine treatments is also contributing to regional growth. For instance, according to the Personalized Medicine Coalition (PMC), a non-profit educational and advocacy group which is dedicated to promoting the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and the healthcare systems, the number of personalized medicines on the market in the United States has increased from 132 in 2016 to 286 in 2020. Digital biomarkers, which are retrieved using portable, wearable, implantable, or digestible digital devices, have also emerged as immersive tools for advancing precision/personalized medicine and supporting clinical testing. For More Information, refer to below link:- Molecular Biomarker Medical Test Market Related Report Thailand Medical Device Market Outlook to 2026F – Driven by prevalence of chronic diseases in the country combined with the government’s supportive policies and the BOI’s incentives Bahrain Blood Gas Analyzer, POC Immunoassay Analyzer and Transcutaneous Monitor Market Outlook to 2026 – Multiple programs to modernize the Bahraini healthcare sector in future including Health Insurance, Health centers and Primary Care Autonomy Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications support@kenresearch.com +91-9015378249 Tags: Abbott Blood-based biomarkers Market Share, AI Technology in Biomarker Market, Asia Pacific Biomarkers Market, BD oncology products Market Share, biomarker IVD providers, Biomarkers products Market, Biomarkers Raw Material Suppliers, blood-based biomarkers Market, Cancer/Oncology Biomarkers Market, Cardiovascular Disorder Biomarkers Market, centogene company profile, CENTOGENE N.V. Hereditary Biomarker Market, challenges in growth of Biomarkers Market, Demand for Biomarkers Devices, digital biomarker market, digital pathology biomarker Market analysis, Distributors of Glass Materials, Emerging Companies in Biomarkers Market, Epigenomics AG Cancer Biomarker Market, Europe Biomarkers Market, General Electric Cancer Biomarker Market, Global Biomarkers Industy, Global Biomarkers Market, Global Biomarkers Market End Users, Global Biomarkers Sector, Global Diagnostic Biomarkers Market, Global Digital Biomarkers Market, Global immunotherapy Market, Global Molecular Biomarkers Market, Global Monitoring Biomarkers Market, Global Neurological Biomarkers Market, Global Predictive Biomarkers Market, Global Prognostic Biomarkers Market, Global Response Biomarkers Market, Global Safety Biomarkers Market, Histologic Biomarkers Market, Immunological Disorder Biomarkers Market, Johnson & Johnson Immunology Biomarker Market, Key Competitors in Biomarkers Market, La Roche Oncology Biomarkers Product Sales, Leading Players in Biomarkers Market, Major Companies in Biomarkers Market, manufacturers of Biomarkers products, Medical Wearables Supplier and Manufacturers, Metabolic Testing Kit Market, Middle East Biomarkers Market, molecular biomarker medical test Market, Molecular Imaging Biomarkers Market, Multi-Biomarker Blood Test Market, Neurological Disorder Biomarkers Market, North America Biomarkers Market, Physiologic Biomarkers Market, POC Diagnostic Medical Device Manufacturers, Radiographic Biomarkers Market, rare disease diagnostics Market, rare disease genetic testing Market, Susceptibility/Risk Biomarkers Market, Thermo Fisher Cancer Biomarker Product Revenue, Top Biomarkers Companies, Ultra-Sensitive Biomarker Detection Device